Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Jin Medical International (ZJYL) over the last 3 years, with Q3 2025 value amounting to $8.1 million.

  • Jin Medical International's Cash & Equivalents rose 1741.35% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 1741.35%. This contributed to the annual value of $8.1 million for FY2025, which is 1741.35% up from last year.
  • Latest data reveals that Jin Medical International reported Cash & Equivalents of $8.1 million as of Q3 2025, which was up 1741.35% from $8.1 million recorded in Q1 2025.
  • Over the past 5 years, Jin Medical International's Cash & Equivalents peaked at $8.1 million during Q1 2025, and registered a low of $4.8 million during Q1 2023.
  • Its 3-year average for Cash & Equivalents is $6.6 million, with a median of $6.9 million in 2024.
  • In the last 5 years, Jin Medical International's Cash & Equivalents skyrocketed by 4458.67% in 2024 and then skyrocketed by 1741.35% in 2025.
  • Quarter analysis of 3 years shows Jin Medical International's Cash & Equivalents stood at $4.8 million in 2023, then skyrocketed by 44.59% to $6.9 million in 2024, then increased by 17.41% to $8.1 million in 2025.
  • Its last three reported values are $8.1 million in Q3 2025, $8.1 million for Q1 2025, and $6.9 million during Q3 2024.